Key findings included enhanced anti-tumor proliferative effects from the combination therapies compared with ALK TKI alone, induction of VEGFR2 expression after exposure to ALK TKI, implicating the role of VEGFR2 signaling with ALK TKI treatment, and lower numbers of CD31-positive blood vessels in mice treated with the combination treatment, suggesting anti-angiogenic efficacy. The gene discussed is KDR; the disease is neoplasm.